Objective: We investigated the diagnostic capacity of CEA and CA 15-3 kinetics for the early detection of metastatic disease in comparison to fixed cut off values.
Methods: In a retrospective analysis, a total of 743 patients with early breast cancer and available baseline values of CEA and CA 15-3 were included. A reproducible increase of 100% of single or combined markers was considered as a strong indicator of metastatic disease.
Results: 187 patients developed metastatic disease and 556 remained disease-free. On the basis of tumor marker kinetics, we reached a specificity of >98% for both biomarkers and a sensitivity of 40.6% for CEA alone, 55.6% for CA 15-3 alone and 66.3% for the combination of both markers. Using fixed cut-off values (CEA: 4ng/mL, CA 15-3: 30U/mL) we ended up with a specificity of 86.3% and a sensitivity of 70.6% for the combination of CEA and CA 15-3. Using higher cut-off values (CEA: 6ng/mL, CA 15-3: 60U/mL) we reached a specificity of 96.9% and a sensitivity of 49.7% for the combination.
Conclusion: We conclude that the interpretation of these markers in follow-up using individual baseline values and kinetics leads to a significant superior profile of specificity and sensitivity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cca.2015.06.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utility of the combination of high fluorescence cells and tumor markers for the diagnosis of malignant pleural effusions.
Clin Biochem
January 2025
Laboratory Department, CLILAB, Sant Joan Despí-Moisès Broggi Hospital, Sant Joan Despí, Spain.
Background: New diagnostic tools have emerged to assist the traditional diagnosis of malignant pleural effusion (MPE), such as high fluorescence cells (HFc) and tumor markers (TMs), determined by clinical laboratory automated pleural fluid workup. This study aimed to evaluate the diagnostic ability of the combination of HFc and TMs for diagnosing MPE.
Methods: We recruited hospitalized patients with pleural effusion at Parc Taulí University Hospital.
Assessment of lipid peroxidation and total antioxidant capacity in patients with breast cancer.
Explor Target Antitumor Ther
January 2025
Department of Medical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Aim: Breast cancer (BC), a disease in which abnormal breast cells grow out of control and form tumors, is a prevalent life-threatening disease worldwide. Oxidative stress has been implicated in the development and progression of various cancers, including BC. Assessing lipid peroxidation and overall antioxidant status in BC offers valuable information on disease progression, patient prognosis, and the effectiveness of therapeutic options.
View Article and Find Full Text PDFThe Effects of Preoperative Serum Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 on the Prognosis of Breast Cancer Patients With Different Molecular Subtypes.
J Clin Med Res
October 2024
Department of Breast and Thyroid Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Background: The aim of the study was to investigate the relationship between serum carcinoembryonic antigen (CEA), cancer antigen 15-3 (CA15-3), and cancer antigen 125 (CA125) levels and traditional clinicopathological factors in patients with early invasive breast cancer in Xinjiang, and the influence of those serum markers on the prognosis of patients with different molecular subtypes.
Methods: We conducted a retrospective study based on the clinical data of 2,940 invasive breast cancer patients who were diagnosed and treated at the Affiliated Cancer Hospital of Xinjiang Medical University from 2015 to 2019. Firstly, in this study, preoperative serum CEA, CA15-3, and CA125 levels were divided into elevated and normal groups based on the optimal cut-off values.
Potential Role of Gene Methylation in Diagnosis of Patients With Breast Cancer.
Clin Med Insights Oncol
October 2024
Biochemistry Department, Biotechnology Research Institute, High Throughput Molecular and Genetic Laboratory, Central Laboratories Network and the Centers of Excellence, National Research Centre, Giza, Egypt.
Article Synopsis
- This study investigates the role of aldo-keto reductase family 1 member B1 (AKR1B1) methylation as a noninvasive biomarker for early diagnosis of breast cancer (BC).
- The research involved 200 Egyptian women, finding that hypermethylation levels were significantly higher in BC cases (93.2%) compared to benign conditions (23.9%) and healthy controls (15.5%).
- Results indicate that hypermethylation is a strong indicator of BC, correlating with tumor severity and early detection, thus highlighting its potential as a valuable diagnostic and prognostic tool in breast cancer management.
Blood endocan as a biomarker for breast cancer recurrence.
Cancer Biomark
October 2024
Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Background: Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.
Objective: This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.
Methods: Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!